Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TRAW
TRAW
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TRAW News
TRAW Reports 2025 Financials and $60 Million Financing Plan
4d ago
Yahoo Finance
Traws Pharma Secures $60 Million Financing for Flu Program Advancement
5d ago
seekingalpha
Traws Pharma Reports FY Earnings and Financing Plan
5d ago
seekingalpha
Traws Pharma Secures $60 Million PIPE Financing
5d ago
NASDAQ.COM
Traws Pharma Announces Clinical Results for Ratutrelvir with Promising Efficacy
Feb 19 2026
Newsfilter
Traws Pharma Advances Ratutrelvir COVID-19 Trial
Jan 26 2026
stocktwits
Traws Pharma Reports Clinical Progress on Ratutrelvir and Tivoxavir Marboxil
Jan 26 2026
Newsfilter
Plus Therapeutics Prices Public Offering, Raising $15 Million
Jan 15 2026
NASDAQ.COM
Traws Pharma's Oral COVID Treatment Demonstrates Results Similar to Paxlovid
Dec 17 2025
Benzinga
Traws Pharma's Ratutrelvir Shows Favorable Tolerability in COVID-19 Treatment
Dec 17 2025
Globenewswire
Traws Pharma's Ratutrelvir Shows Favorable Tolerability in COVID-19 Treatment
Dec 17 2025
Newsfilter
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Dec 15 2025
NASDAQ.COM
Linde Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Wednesday
Dec 03 2025
Benzinga
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
Oct 30 2025
PRnewswire
Dover, Delaware -- Expert Systems Inc. Backs Traws Pharma's Phase 2 Clinical Trials for Ratutrelvir, an Innovative Ritonavir-Free Antiviral Treatment for COVID-19.
Oct 22 2025
Newsfilter
Annovis Names Mark Guerin as CFO
Sep 24 2025
Globenewswire
Show More News
